Abstract
Purpose :
To evaluate 7-year clinical outcomes in patient with central serous chorioretinopathy (CSC) according to age at presentation.
Methods :
This retrospective study reviewed clinical and multimodal imaging data (color fundus photography, optical coherence tomography, fundus autofluorescence, fluorescein angiography, indocyanine green angiography) of 75 eyes of 71 patients with CSC. All subjects were followed up at least 7 years. The eyes were divided into 3 groups according to age at presentation, as <50 years old (Group 1, 28 eyes), 50 to 59 years old (Group 2, 28 eyes), and ≥60 years old (Group 3, 19 eyes). Best corrected visual acuity (BCVA), subfoveal choroidal thickness (SFCT), central subfield retinal thickness (CST), multimodal imaging were analyzed.
Results :
At baseline, mean BCVA and mean CST among three groups were statistically different (BCVA; p = 0.047, CST; p = 0.034). Seven-year mean change of SFCT were -7.0 ± 56.7 μm in Group 1, -12.3 ± 51.0 μm in Group 2, and -66.4 ± 57.6 μm in Group 3. Mean SFCT in Group 3 significantly decreased compared to that of other groups (p =0.004; compared to Group 1, p=0.016; compared to Group 2). Seven-year prevalence of shallow RPE elevation was 10.7% in Group 1, 25.0% in Group 2, 42.1% in Group 3. Seven-year prevalence of choroidal neovascularization (CNV) was 7.1% in Group 1, 14.3% in Group 2, 36.8% in Group 3. In older age group (over 50), advanced fundus autofluorescence patterns appeared and progressed during 7-year follow-up.
Conclusions :
During 7-year follow up of CSC, mean subfoveal choroidal thickness decreased by 7.0 μm in age 30-49, by 12.3 μm in age 50-59, and by 66.4 μm in age over 60 which was significantly different. Age at presentation were associated with decreases of choroidal thickness. In CSC, long-term and planned researches are needed.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.